Bevacizumab: overview of the literature
作者： Maria Ignez Braghiroli , Jorge Sabbaga , Paulo M Hoff
DOI: 10.1586/ERA.12.13
关键词:
摘要: … for bevacizumab activity. However, even though a Phase I trial did find that bevacizumab-… slightly higher baseline VEGF levels than bevacizumab recipients with progressive disease […
expert-reviews.com参考文章(114)
H. A. Wakelee, S. E. Dahlberg, S. M. Keller, D. R. Gandara, S. L. Graziano, N. B. Leighl, A. A. Adjei, J. H. Schiller, , Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 29, pp. 7013- 7013 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.7013
D R Senger, L Van de Water, J Feder, H F Dvorak, D T Connolly, Purification and NH2-Terminal Amino Acid Sequence of Guinea Pig Tumor-secreted Vascular Permeability Factor Cancer Research. ,vol. 50, pp. 1774- 1778 ,(1990)
Jorge A. Garcia, Tarek Mekhail, Paul Elson, Pierre Triozzi, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski, Brian I Rini, Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial BJUI. ,vol. 107, pp. 562- 570 ,(2011) , 10.1111/J.1464-410X.2010.09573.X
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Pragada Sriramarao, Per Borgström, Napolenone Ferrara, Kenneth J. Hillan, Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-Vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy Cancer Research. ,vol. 56, pp. 4032- 4039 ,(1996)
T. Cloughesy, J. J. Vredenburgh, B. Day, A. Das, H. S. Friedman, , Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. Journal of Clinical Oncology. ,vol. 28, pp. 2008- 2008 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.2008
Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael D. Prados, Victor A. Levin, W.K. Alfred Yung, Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials Journal of Clinical Oncology. ,vol. 17, pp. 2572- 2578 ,(1999) , 10.1200/JCO.1999.17.8.2572
Jeanette M Wood, G Bold, Elizabeth Buchdunger, R Cozens, Stefano Ferrari, Jörg Frei, F Hofmann, Jürgen Mestan, H Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, A Theuer, Harry Towbin, Fritz Wenger, K Woods-Cook, A Menrad, Gerhard Siemeister, M Schirner, Karl-Heinz Thierauch, Martin R Schneider, J Drevs, G Martiny-Baron, F Totzke, Dieter Marmé, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Research. ,vol. 60, pp. 2178- 2189 ,(2000)
K. Margolin, M. S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, J. Breed, Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Journal of Clinical Oncology. ,vol. 19, pp. 851- 856 ,(2001) , 10.1200/JCO.2001.19.3.851
Y S Lin, J L Mendoza, D Fei, N B Modi, C Nguyen, Y G Meng, E Escandon, Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor Journal of Pharmacology and Experimental Therapeutics. ,vol. 288, pp. 371- 378 ,(1999)